Ambrx breaks deal mold with Zhejiang ADC alliance
This article was originally published in Scrip
Executive Summary
Research-based alliances between Chinese and Western pharma/biotech partners have been on an upward arc over the past year, driven by the desire of smaller US and European companies to gain access to China's growing market and their Chinese counterparts' rising hunger for innovation.